Mark A Socinski Selected Research

Gemcitabine

10/2019	A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
6/2016	The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
1/2016	Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
7/2015	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
4/2013	A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
5/2012	Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
9/2011	A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
5/2011	A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.
12/2010	A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
7/2010	A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark A Socinski Research Topics

Disease

162	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 03/2002
75	Neoplasms (Cancer) 12/2023 - 10/2002
32	Lung Neoplasms (Lung Cancer) 01/2023 - 11/2004
28	Disease Progression 11/2023 - 09/2002
23	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2017 - 04/2003
18	Neutropenia 01/2021 - 11/2002
10	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2006
9	Carcinoma (Carcinomatosis) 10/2023 - 09/2002
9	Adenocarcinoma 01/2023 - 08/2009
9	Adenocarcinoma of Lung 01/2021 - 11/2006
9	Thrombocytopenia (Thrombopenia) 01/2018 - 10/2006
8	Leukemia 01/2017 - 04/2003
7	Brain Neoplasms (Brain Tumor) 01/2022 - 09/2007
7	Fatigue 01/2018 - 06/2005
7	Exanthema (Rash) 10/2017 - 04/2005
6	Anemia 01/2021 - 10/2009
6	Febrile Neutropenia 01/2020 - 04/2008
5	Pneumonia (Pneumonitis) 06/2020 - 07/2002
5	Esophagitis 05/2013 - 10/2002
4	Infections 11/2022 - 12/2014
4	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 08/2003
4	Hypertension (High Blood Pressure) 01/2020 - 04/2008
4	Hemorrhage 01/2018 - 04/2008
3	Colorectal Neoplasms (Colorectal Cancer) 10/2023 - 08/2007
3	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 04/2007
3	Leukopenia 01/2018 - 10/2009
3	Diarrhea 10/2017 - 11/2002
3	Nausea 10/2017 - 04/2005
3	Mucositis 01/2017 - 04/2005
2	COVID-19 11/2022 - 01/2022
2	Cough 01/2018 - 07/2002
2	Malignant Mesothelioma 11/2017 - 04/2005
2	Acne Vulgaris 07/2015 - 11/2008
2	Melanoma (Melanoma, Malignant) 02/2014 - 05/2013
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2012 - 10/2010

Drug/Important Bio-Agent (IBA)

56	Carboplatin (JM8)FDA LinkGeneric 11/2023 - 09/2002
44	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 07/2002
30	Bevacizumab (Avastin)FDA Link 11/2023 - 09/2007
26	PlatinumIBA 10/2023 - 09/2002
25	Pemetrexed (MTA)FDA Link 11/2023 - 04/2005
22	Gemcitabine FDA Link 10/2019 - 07/2002
16	ErbB Receptors (EGF Receptor)IBA 10/2023 - 08/2007
14	Docetaxel (Taxotere)FDA Link 01/2020 - 09/2002
13	Tyrosine Kinase InhibitorsIBA 11/2023 - 05/2007
12	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 11/2002
11	Immune Checkpoint InhibitorsIBA 07/2023 - 02/2014
11	130-nm albumin-bound paclitaxelIBA 01/2021 - 05/2008
11	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 08/2009
10	atezolizumabIBA 11/2023 - 06/2018
9	Monoclonal AntibodiesIBA 02/2022 - 04/2008
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2010
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022 - 02/2008
7	necitumumabIBA 10/2019 - 03/2015
7	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 01/2005
7	Gefitinib (Iressa)FDA Link 01/2017 - 06/2006
7	SolventsIBA 01/2016 - 10/2007
6	B7-H1 AntigenIBA 01/2021 - 10/2015
6	Sunitinib (Sutent)FDA Link 01/2017 - 02/2008
6	Irinotecan (Camptosar)FDA LinkGeneric 03/2008 - 10/2002
5	Albumin-Bound Paclitaxel FDA Link 01/2021 - 10/2007
5	CrizotinibIBA 10/2020 - 01/2011
5	AntibodiesIBA 01/2018 - 08/2007
4	Anaplastic Lymphoma KinaseIBA 10/2020 - 12/2014
4	NivolumabIBA 01/2017 - 01/2015
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2015 - 05/2007
4	taxaneIBA 01/2014 - 07/2002
4	Vinorelbine (Navelbine)FDA LinkGeneric 07/2008 - 06/2004
3	Circulating Tumor DNAIBA 11/2023 - 01/2022
3	Biosimilar PharmaceuticalsIBA 11/2023 - 01/2015
3	nintedanibIBA 01/2018 - 12/2011
3	alectinibIBA 01/2018 - 02/2016
3	LigandsIBA 10/2015 - 03/2010
3	Proteins (Proteins, Gene)FDA Link 09/2014 - 01/2011
2	durvalumabIBA 12/2023 - 11/2021
2	RNA (Ribonucleic Acid)IBA 10/2023 - 01/2023
2	HM781-36BIBA 01/2023 - 01/2022
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 12/2011
2	AlbuminsIBA 01/2021 - 10/2012
2	RamucirumabIBA 01/2020 - 01/2018
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 08/2017 - 10/2015
2	STA 9090IBA 05/2015 - 06/2013
2	Topotecan (Hycamtin)FDA LinkGeneric 12/2014 - 01/2005
2	pazopanib FDA Link 11/2014 - 12/2011
2	EnzymesIBA 09/2014 - 04/2005
2	AntigensIBA 02/2014 - 01/2014
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2013 - 08/2009
2	Hematoxylin (Haematoxylon)IBA 01/2013 - 08/2009
2	Taxoids (Taxanes)IBA 10/2012 - 07/2002

Therapy/Procedure

91	Therapeutics 03/2024 - 03/2002
67	Drug Therapy (Chemotherapy) 03/2024 - 03/2002
23	Radiotherapy 11/2017 - 10/2002
10	Combined Modality Therapy 03/2008 - 10/2004
9	Immunotherapy 03/2024 - 01/2014
8	Chemoradiotherapy 11/2021 - 07/2005
5	Conformal Radiotherapy 11/2011 - 10/2002
4	Induction Chemotherapy 09/2017 - 03/2008
3	Duration of Therapy 07/2009 - 03/2002
2	Precision Medicine 01/2023 - 11/2010
2	Aftercare (After-Treatment) 01/2018 - 05/2017
2	Intravenous Infusions 06/2013 - 02/2008